MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

pharmafile | October 8, 2018 | News story | Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis 

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs.

The deal between the multibillion dollar pharma firm MSD, and the Samsung Biologics and Biogen Idec joint-venture Samsung Bioepis, will see MSD supply Renflexis, a biosimilar of Janssen’s Remicade (Infliximab) to the US federal agency that provides healthcare services to military veterans.

The deal comes after a 2013 deal between MSD and Samsung Bioepis settled that Merck would be responsible for commercialising multiple biosimilar candidates, in particular partnered territories.

Meanwhile Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and regulatory registration.

The biosimilar of the blockbuster monoclonal antibody which is used to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, psoriasis and rheumatoid arthritis gained FDA approval in April 2017.

Louis Goss

Related Content

Biogen Phase III choroideremia study did not meet primary endpoint

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia …


Janssen CLL treatment combination sees success in trials

Janssen has announced positive data from its Phase III GLOW study, with the combination of …


MSD announce new data from advanced renal cell carcinoma trial

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) …

Latest content